Efficacy and Safety Study of Apixaban for Extended Treatment of Deep Vein Thrombosis or Pulmonary Embolism

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
Bristol-Myers Squibb
ClinicalTrials.gov Identifier:
NCT00633893
First received: March 5, 2008
Last updated: October 30, 2013
Last verified: October 2013
  Purpose

The purpose is to evaluate the effects of an investigational blood thinner, apixaban, in preventing venous thromboembolic (VTE) recurrence or death in patients who have completed their intended treatment for deep vein thrombosis (DVT) or pulmonary embolism (PE)


Condition Intervention Phase
Venous Thrombosis
Drug: Apixaban
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: A Safety and Efficacy Trial Evaluating the Use of Apixaban for the Extended Treatment of Deep Vein Thrombosis and Pulmonary Embolism

Resource links provided by NLM:


Further study details as provided by Bristol-Myers Squibb:

Primary Outcome Measures:
  • Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    VTE included: nonfatal deep vein thrombosis (DVT) or nonfatal pulmonary embolism (PE). All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.

  • Adjudicated Composite of Symptomatic, Recurrent Venous Thromboembolism (VTE) or All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 months ] [ Designated as safety issue: No ]
    VTE included: nonfatal DVT or nonfatal PE. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted. Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.


Secondary Outcome Measures:
  • Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or VTE-related Death During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: Yes ]
    VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate (proportion of participants with event) calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. For missing endpoint data, participants were imputed as having had a primary efficacy outcome event.

  • Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) -Related Death During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    VTE includes nonfatal DVT or nonfatal PE. All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Composite endpoint included events that occurred any time from randomization until end of the intended treatment period, regardless of whether the participants were receiving drug treatment. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. If there were missing endpoint data, participants were imputed as having had an efficacy outcome event.

  • Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period: longer of the dosing period plus 2 days (completed treatment) or 355 days (discontinued early). Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits.

  • Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

  • Adjudicated Venous Thromboembolism (VTE) - Related Death During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    VTE-related death defined as: PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation).

  • Adjudicated Cardiovascular (CV)-Related Death During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

  • Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population With Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Participants with missing endpoint information were classified as having had the efficacy event (imputation). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

  • Number of Participants With an Adjudicated Symptomatic Nonfatal Venous Thromboembolism (VTE) Recurrence or Death (All Cause) During the Intended Treatment Period - Randomized Participants Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    All index events, DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. First event category was the first primary event for each participant and each participant was counted once. CV-related death was presented excluding VTE-related death. In participants with event category, each participant was counted once in each event category but could have been counted in multiple categories. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.

  • Adjudicated Major Bleeding During the Treatment Period - Treated Population [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: Yes ]
    Major bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 grams per deciliter (g/dL) or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 milliliters (mL) or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ; or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

  • Adjudicated Composite of Major/Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: Yes ]
    Major bleeding and clinically relevant non-major bleeding were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Major bleeding was defined as acute clinically overt bleeding: associated with a fall in hemoglobin of 2 g/dL or more, or leading to a transfusion of 2 or more units of packed red blood cells or 1000 mL or more of whole blood, or in a critical site: intracranial, intraspinal, intraocular, pericardial, intra-articular, intramuscular with compartment syndrome, retroperitoneal, or another critical organ or is fatal. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

  • Adjudicated Clinically Relevant Non-major Bleeding During the Treatment Period - Treated Participants [ Time Frame: Day 1 up to 12 months ] [ Designated as safety issue: Yes ]
    Non-major clinically relevant bleeding was adjudicated/confirmed by a central independent adjudication committee blinded to treatment and defined as: acute clinically overt bleeding compromising hemodynamics; leading to hospitalization; traumatic subcutaneous hematoma; intramuscular hematoma; epistaxis that lasted for more than 5 minutes, was repetitive or led to an intervention; spontaneous gingival bleeding (or lasting more than 5 minutes); spontaneous hematuria (macroscopic or lasted more than 24 hours after instrumentation of the urogenital tract); macroscopic gastrointestinal hemorrhage (including at least 1 episode of melena or hematemesis (if clinically apparent with positive results on a fecal occult-blood test); rectal blood loss. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits.

  • Adjudicated Clinically Relevant Minor Bleeding During the Treatment Period - Treated Participants [ Time Frame: Day 1 up to 12 months ] [ Designated as safety issue: Yes ]
    All bleeding events were reviewed by the central independent adjudication committee blinded to treatment and classified as major bleeding, clinically relevant non-major bleeding, minor bleeding or no bleeding. If event was not major or clinically relevant non-major, it was judged to be minor. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Confidence interval (CI) for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

  • Adjudicated Total Bleeding During the Treatment Period - Treated Participants [ Time Frame: Day 1 up to 12 months ] [ Designated as safety issue: Yes ]
    All bleeding events were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Total bleeding was defined as any major, clinically relevant non-major, or minor bleeding. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). CI for single event rate was calculated based on the Wald asymptotic confidence limits. Treated population includes randomized participants who received at least one dose of study drug.

  • Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Venous Thromboembolism-related Death During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: Yes ]
    VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints.

  • Adjudicated Composite of Recurrent, Symptomatic Venous Thromboembolism (VTE) or Cardio Vascular (CV) - Related Death During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event. Index events of DVT and/or PE, along with myocardial infarction and stroke were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Composite endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for these endpoints; participants who had an event during the intended treatment period were counted.

  • Adjudicated Nonfatal Deep Vein Thrombosis (DVT) During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    DVT was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

  • Adjudicated Nonfatal Pulmonary Embolism (PE) During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: No ]
    PE was adjudicated/confirmed by a central independent adjudication committee blinded to treatment: PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

  • Adjudicated Venous Thromboembolism (VTE)- Related Death During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: Yes ]
    VTE related death defined as PE (based on objective diagnostic testing, autopsy), unexplained death (and VTE cannot be ruled out), sudden death (and VTE cannot be ruled out). DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, and death, were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint.

  • Adjudicated Cardio Vascular (CV)-Related Death During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: Yes ]
    CV-related death was defined as myocardial infarction, stroke, or other specified cardiovascular event and these were adjudicated/confirmed by a central independent adjudication committee blinded to treatment. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.

  • Adjudicated All-Cause Death During the Intended Treatment Period - Randomized Population Without Imputation [ Time Frame: Day 1 up to 12 Months ] [ Designated as safety issue: Yes ]
    DVT and/or PE were adjudicated/confirmed by a central independent adjudication committee blinded to treatment: DVT assessed by compression ultrasound and/or venography; PE assessed by spiral computed tomography scanning, pulmonary angiography, and/or ventilation/perfusion lung scan. New/recurrent VTE, death, venous/arterial thromboembolic events, bleeding, thrombocytopenia, acute myocardial infarction and stroke were also adjudicated. Event rate is proportion of participants with event; calculated as n/N (n=number of events; N=number of participants). Intended treatment period was defined as the longer of the dosing period plus 2 days or 355 days. Endpoint included events at any time from randomization until end of the intended treatment period, regardless whether drug treatment was received. No imputation was done for this endpoint; participants who had an event during the intended treatment period were counted.


Enrollment: 2711
Study Start Date: May 2008
Study Completion Date: August 2012
Primary Completion Date: August 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1
2.5 mg
Drug: Apixaban
Tablets, Oral, twice daily, 12 months
Other Name: BMS-562247
Experimental: 2
5.0 mg
Drug: Apixaban
Tablets, Oral, twice daily, 12 months
Other Name: BMS-562247
Active Comparator: 3
0 mg
Drug: Placebo
Tablets, Oral, twice daily, 12 months

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men and women ≥ 18 years of age;
  • Clinical diagnosis of Deep Vein Thrombosis (DVT) or Pulmonary Embolism (PE);
  • Anticoagulant treatment completed
  • No recurrence of Venous Thromboembolism (VTE)

Exclusion Criteria:

  • Subjects with indications for long-term treatment with a vitamin K antagonist
  • Active bleeding or high risk for serious bleeding
  • Short life expectancy
  • Uncontrolled high blood pressure
  • Impaired kidney or liver function
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00633893

  Hide Study Locations
Locations
United States, Alabama
Alabama Clinical Therapeutics, Llc
Birmingham, Alabama, United States, 35235
United States, Arizona
Cardiovascular Consultants, Ltd.
Phoenix, Arizona, United States, 85032
Robert J. Bloomberg, Md, Pc
Tempe, Arizona, United States, 85283
United States, Arkansas
Fort Smith Lung Center
Fort Smith, Arkansas, United States, 72901
United States, California
Beaver Medical Group
Banning, California, United States, 92220
Scripps Clinic/Scripps Health And Green Hospital
La Jolla, California, United States, 92037
Healthcare Partners Medical Group
Los Angeles, California, United States, 90015
Mission Internal Medical Group
Mission Viejo, California, United States, 92691
Desert Med Grp Inc, Dba Desert Oasis Healthcare Med Group
Palm Springs, California, United States, 92262
Indus Clinical Research Institute, Inc.
Pomona, California, United States, 91767
Kaiser Permanente Medical Center
San Francisco, California, United States, 94118
Stanford University Medical Center
Stanford, California, United States, 94305
Harbor Ucla Medical Center
Torrance, California, United States, 90509
Progressive Clinical Research
Vista, California, United States, 92083
United States, Colorado
Rocky Mountain Internal Medicine
Aurora, Colorado, United States, 80012
New West Physicians
Golden, Colorado, United States, 80401
United States, Delaware
Alfieri Cardiology
Newark, Delaware, United States, 19713
United States, Florida
Bay Pines Va Healthcare Systems
Bay Pines, Florida, United States, 33744
St. Francis Sleep Allergy & Lung Institute
Clearwater, Florida, United States, 33765
Research Alliance, Inc.
Clearwater, Florida, United States, 33756
Berma Research Group
Fort Lauderdale, Florida, United States, 33316
Healthworx
Hollywood, Florida, United States, 33021
Hematology Oncology Associates
Loxahatchee, Florida, United States, 33470
South Miami Heart Center
Miami, Florida, United States, 33143
Physicians Regional Medical Group
Naples, Florida, United States, 34119
Richard A. Mclean M.D., P.A.
Plantation, Florida, United States, 33317
Tampa Clinical Research
Tampa, Florida, United States, 33624
Primary Care Of The Treasure Coast, Inc.
Vero Beach, Florida, United States, 32960
Cleveland Clinic Florida
Weston, Florida, United States, 33331
United States, Georgia
Vascular Surgical Associates, Pc
Austell, Georgia, United States, 30106
Atlanta Institute For Medical Research, Inc
Decatur, Georgia, United States, 30030
Gwinnett Biomedical Research
Lawrenceville, Georgia, United States, 30046
United States, Idaho
Boise Orthopedic Clinic
Boise, Idaho, United States, 83706
Saltzer Medical Group
Nampa, Idaho, United States, 83686
United States, Indiana
Infectious Disease Of Indiana Psc
Carmel, Indiana, United States, 46032
Office Of:Eugene C. Fletcher, Md
New Albany, Indiana, United States, 47150
United States, Iowa
Heartland Vascular Medicine And Surgery
Windsor Heights, Iowa, United States, 50324
United States, Kentucky
Kentucky Lung Clinic
Hazard, Kentucky, United States, 41701
Owensboro Heart & Vascular
Owensboro, Kentucky, United States, 42303
United States, Maine
Pen Bay Medical Center
Rockport, Maine, United States, 04856
United States, Maryland
Anne Arundel Health System Research Institute, Inc.
Annapolis, Maryland, United States, 21401
United States, Massachusetts
Cape Cod Research Institute
Hyannis, Massachusetts, United States, 02601
United States, Michigan
Henry Ford Hospital
Detroit, Michigan, United States, 48202
William Beaumont Hospital
Royal Oak, Michigan, United States, 48073
United States, Missouri
Veterans Affairs Medical Center
Kansas City, Missouri, United States, 64128
United States, Montana
Mercury Street Medical Group, Pllc
Butte, Montana, United States, 59701
Great Falls Clinic, Llp
Great Falls, Montana, United States, 59405
United States, Nebraska
Internal Medical Associates Of Grand Island, P.C
Grand Island, Nebraska, United States, 68803
Creighton University Medical Center
Omaha, Nebraska, United States, 68131
United States, New York
Kaleida Health System
Buffalo, New York, United States, 14209
Goshen Medical Associates
Goshen, New York, United States, 10924
Sjh Cardiology Associates
Liverpool, New York, United States, 13088
Richmond University Medical Center
Staten Island, New York, United States, 10310
New York Medical College
Valhalla, New York, United States, 10595
United States, North Carolina
Thomas L. Ortel, Md, Phd
Durham, North Carolina, United States, 27710
Valley Internal Medicine
Fayetteville, North Carolina, United States, 28304
Rex Healthcare
Raleigh, North Carolina, United States, 27607
Piedmont Healthcare/Research
Statesville, North Carolina, United States, 28625
Whiteville Medical Associates, P.A.
Whiteville, North Carolina, United States, 28472
Wilmington Medical Research
Wilmington, North Carolina, United States, 28401
United States, Ohio
Akron General Medical Center
Akron, Ohio, United States, 44307
Community Health Care, Inc.
Canal Fulton, Ohio, United States, 44614
Valley Medical Research
Centerville, Ohio, United States, 45459
Ohio State University Medical Center
Columbus, Ohio, United States, 43210
Remington Davis Inc.
Columbus, Ohio, United States, 43215
Jobst Vascular Center At The Toledo Hospital
Toledo, Ohio, United States, 43606
United States, Oklahoma
Cor Clinical Research, Llc
Oklahoma City, Oklahoma, United States, 73103
United States, Pennsylvania
Pma Medical Specialists
Phoenixville, Pennsylvania, United States, 19460
United States, Rhode Island
Rhode Island Hospital
Providence, Rhode Island, United States, 02903
United States, South Carolina
Charleston Hematology Oncology Associates, Pa
Charleston, South Carolina, United States, 29414
Greenville Hospital System
Greenville, South Carolina, United States, 29615
Three Rivers Medical Associates, Pa
Irmo, South Carolina, United States, 29063
Clinical Research Authority, Llc
Murrells Inlet, South Carolina, United States, 29576
Palmetto Clinical Research
Summerville, South Carolina, United States, 29485
United States, Tennessee
Holston Medical Group
Bristol, Tennessee, United States, 37620
Holston Medical Group
Kingsport, Tennessee, United States, 37660
United States, Texas
Amarillo Heart Clinical Research Institute Inc.
Amarillo, Texas, United States, 79106
Corsicana Medical Research
Corsicana, Texas, United States, 75110
Ankur Doshi, Md
Houston, Texas, United States, 77024
Northwest Heart Center
Tomball, Texas, United States, 77375
United States, Utah
Tanner Clinic
Layton, Utah, United States, 84041
University Of Utah Hospital
Salt Lake City, Utah, United States, 84132
United States, Virginia
University Of Virginia Health System
Charlottesville, Virginia, United States, 22908
Sentara York Clinical Research
Norfolk, Virginia, United States, 23510
United States, Washington
Lake Washington Vascular, Pllc
Bellevue, Washington, United States, 98004
Franciscan Research Center
Tacoma, Washington, United States, 98405
United States, Wisconsin
Medical Assoicates Inc.
Menomonee Falls, Wisconsin, United States, 53051
Argentina
Local Institution
Capital Federal, Buenos Aires, Argentina, C1426ANZ
Local Institution
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, 1093 AAS
Local Institution
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, C1437JCP
Local Institution
Ciudad Autonoma De Buenos Aire, Buenos Aires, Argentina, C1180AAX
Local Institution
Ciudad De Buenos Aires, Buenos Aires, Argentina, C1181ACH
Local Institution
Ciudad De Buenos Aires, Buenos Aires, Argentina, C1034ACO
Local Institution
Coronel Suarez, Buenos Aires, Argentina, B7540GHD
Local Institution
La Plata, Buenos Aires, Argentina, 1900
Local Institution
La Plata, Buenos Aires, Argentina, B1902COI
Local Institution
Mar Del Plata, Buenos Aires, Argentina, 7600
Local Institution
San Martin, Buenos Aires, Argentina, B1650CSQ
Local Institution
Rosario, Santa Fe, Argentina, S2000DSV
Local Institution
Rosario, Santa Fe, Argentina, S2002KDS
Local Institution
Rosario, Santa Fe, Argentina, S2000CVB
Local Institution
Buenos Aires, Argentina, C1431FWO
Local Institution
Buenos Aires, Argentina, C1122AAL
Local Institution
Buenos Aires, Argentina, C1280AEB
Local Institution
Cordoba, Argentina, 5000
Local Institution
Cordoba, Argentina, X5000JHQ
Local Institution
Corrientes, Argentina, 3400
Australia, Australian Capital Territory
Local Institution
Garran, Australian Capital Territory, Australia, 2605
Australia, New South Wales
Local Institution
Kogarah, New South Wales, Australia, 2217
Local Institution
Lismore, New South Wales, Australia, 2480
Local Institution
St Leonards, New South Wales, Australia, 2065
Australia, Queensland
Local Institution
Herston, Queensland, Australia, 4029
Local Institution
Kippa Ring, Queensland, Australia, 4021
Local Institution
Woolloongabba, Queensland, Australia, 4102
Australia, South Australia
Local Institution
Adelaide, South Australia, Australia, 5000
Local Institution
Bedford Park, South Australia, Australia, 5042
Australia, Tasmania
Local Institution
Launceston, Tasmania, Australia, 7250
Australia, Victoria
Local Institution
Box Hill, Victoria, Australia, 3128
Local Institution
Clayton, Victoria, Australia, 3168
Local Institution
Footscray, Victoria, Australia, 3011
Local Institution
Parkville, Victoria, Australia, 3050
Local Institution
Richmond, Victoria, Australia, 3121
Local Institution
Ringwood East, Victoria, Australia, 3135
Local Institution
Windsor, Victoria, Australia, 3181
Australia, Western Australia
Local Institution
Perth, Western Australia, Australia, 6000
Austria
Local Institution
Graz, Austria, 8036
Local Institution
Innsbruck, Austria, A-6020
Local Institution
Vienna, Austria, 1090
Local Institution
Vienna, Austria, 1100
Local Institution
Wien, Austria, 1090
Local Institution
Wien, Austria, 1140
Brazil
Local Institution
Salvador, Bahia, Brazil, 40144 900
Local Institution
Brasilia, Distrito Federal, Brazil, 70335
Local Institution
Belo Horizonte - Mg, Minas Gerais, Brazil, 30150
Local Institution
Belo Horizonte - Mg, Minas Gerais, Brazil, 30130
Local Institution
Curitiba, Parana, Brazil, 80810
Local Institution
Curitiba, Parana, Brazil, 80050
Local Institution
Curitiba, Parana, Brazil, 80030
Local Institution
Curitiba, Parana, Brazil, 81520
Local Institution
Rio Janeiro, Rio De Janeiro, Brazil, 22280
Local Institution
Port Alegre, Rio Grande Do Sul, Brazil, 90020
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 90035
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 9110270
Local Institution
Porto Alegre, Rio Grande Do Sul, Brazil, 90610
Local Institution
Botucatu, Sao Paulo, Brazil, 18618
Local Institution
Campinas, Sao Paulo, Brazil, 13083
Local Institution
Santo Andre - Sp, Sao Paulo, Brazil, 09060
Local Institution
Sao Jose Do Rio Preto, Sao Paulo, Brazil, 15015
Local Institution
Sao Jose Do Rio Preto, Sao Paulo, Brazil, 15090
Local Institution
Rio De Janeiro, Brazil, 20551
Local Institution
Sao Paulo, Brazil, 01323
Local Institution
Sao Paulo, Brazil, 05403
Local Institution
Sao Paulo, Brazil, 04005
Local Institution
Sao Paulo, Brazil, 01509
Canada, Alberta
Local Institution
Edmonton, Alberta, Canada, T5H 4B9
Local Institution
Edmonton, Alberta, Canada, Tsa 4l8
Local Institution
Edmonton, Alberta, Canada, T5X 3N5
Canada, British Columbia
Local Institution
Kelowna, British Columbia, Canada, V1Y 9L8
Local Institution
Victoria, British Columbia, Canada, V8R 4R2
Canada, Ontario
Local Institution
Hamilton, Ontario, Canada, L8S 4K1
Local Institution
Hamilton, Ontario, Canada, L8L 2X2
Local Institution
Toronto, Ontario, Canada, M5G 2C4
Local Institution
Waterloo, Ontario, Canada, N2J 1C4
Local Institution
Windsor, Ontario, Canada, N8X 5A6
Canada, Quebec
Local Institution
Montreal, Quebec, Canada, H3G 1A4
Local Institution
Montreal, Quebec, Canada, H3T 1M5
Local Institution
Montreal, Quebec, Canada, H1T 2M4
Local Institution
Pointe- Claire, Quebec, Canada, H9R 3J1
Local Institution
St. Jerome, Quebec, Canada, J7Z 5T3
Canada
Local Institution
Quebec, Canada, G1V 4G5
Chile
Local Institution
Temuco, Araucania, Chile, 4781173
Local Institution
Punta Arenas, Magallanes Antartica, Chile, 6212296
Local Institution
Independencia, Metropolitana, Chile, XXXXX
Local Institution
Santiago, Metropolitana, Chile, 7500520
Local Institution
Santiago, Metropolitana, Chile, 7600448
Local Institution
Santiago, Metropolitana, Chile, 7980378
Local Institution
Santiago, Metropolitana, Chile, 8330024
Local Institution
Vina Del Mar, Valparaiso, Chile, 2520000
Czech Republic
Local Institution
Kladno, Czech Republic, 272 59
Local Institution
Litomysl, Czech Republic, 570 14
Local Institution
Mestec Kralove, Czech Republic, 289 03
Local Institution
Ostrava Vitkovice, Czech Republic, 703 00
Local Institution
Plzen, Czech Republic, 323 33
Local Institution
Praha 1, Czech Republic, 118 33
Local Institution
Praha 1, Czech Republic, 110 00
Local Institution
Praha 13, Czech Republic, 158 00
Local Institution
Praha 2, Czech Republic, 128 08
Local Institution
Praha 2, Czech Republic, 120 00
Local Institution
Praha 2, Czech Republic, 121 11
Local Institution
Praha 4, Czech Republic, 140 21
Local Institution
Usti Nad Orlici, Czech Republic, 562 18
Denmark
Local Institution
Arhus C, Denmark, 8000
Local Institution
Braedstrup, Denmark, 8740
Local Institution
Esbjerg, Denmark, 6700
Local Institution
Frederiksberg, Denmark, 2000
Local Institution
Hellerup, Denmark, 2900
Local Institution
Herning, Denmark, 7400
Local Institution
Hilleroed, Denmark, 3400
Local Institution
Naestved, Denmark, 4700
Local Institution
Silkeborg, Denmark, 8600
France
Local Institution
Arras, France, 62022
Local Institution
Besancon, France, 25000
Local Institution
Brest Cedex, France, 29609
Local Institution
Clamart, France, 92141
Local Institution
Clermont-Ferrand Cedex 01, France, 63003
Local Institution
Dijon, France, 21079
Local Institution
Grenoble, France, 38043
Local Institution
Le Kremlin-Bicetre, France, 94275
Local Institution
Lille Cedex, France, 59020
Local Institution
Limoges Cedex, France, 87042
Local Institution
Lyon Cedex 03, France, 69437
Local Institution
Nantes, France, 44093
Local Institution
Saint-Priest En Jarez, France, 42270
Local Institution
Toulouse Cedex 9, France, 31059
Local Institution
Vernon, France, 27200
Germany
Local Institution
Berlin, Germany, 14050
Local Institution
Berlin, Germany, 10787
Local Institution
Berlin, Germany, 10117
Local Institution
Bochum, Germany, 44791
Local Institution
Bonn, Germany, 53115
Local Institution
Cologne, Germany, 50937
Local Institution
Dortmund, Germany, 44137
Local Institution
Dresden, Germany, 01067
Local Institution
Dresden, Germany, 01307
Local Institution
Erfurt, Germany, 99089
Local Institution
Frankfurt, Germany, 60596
Local Institution
Gottingen, Germany, 37075
Local Institution
Karlsbad, Germany, 76307
Local Institution
Krefeld, Germany, 47805
Local Institution
Ludwigshafen, Germany, 67063
Local Institution
Mannheim, Germany, 68165
Local Institution
Mannheim, Germany, 68161
Local Institution
Mannheim, Germany, 68167
Local Institution
Munchen, Germany, 80331
Local Institution
Munich, Germany, 80336
Hong Kong
Local Institution
Hong Kong, Hong Kong
Local Institution
Shatin, N.T, Hong Kong
India
Local Institution
Hyderabad, Andhra Pradesh, India, 500034
Local Institution
Hyderabad, Andhra Pradesh, India, 500 082
Local Institution
Ahmedabad, Gujarat, India, 380006
Local Institution
Gurgaon, Haryana, India, 122001
Local Institution
Bangalore, Karnataka, India, 560054
Local Institution
Bengaluru, Karnataka, India, 560017
Local Institution
Kochi, Kerala, India, 682041
Local Institution
Pune, Maharashtra, India, 411001
Local Institution
Mohali, Punjab, India, 160062
Local Institution
Ludhiana, Tagore Nagar, India, 141001
Local Institution
Chennai, Tamil Nadu, India, 600 006
Local Institution
Ahmedabad, India, 380015
Local Institution
Bangalore, India, 560052
Local Institution
Bangalore, Karnataka, India, 560034
Local Institution
Chennai, India, 600 003
Local Institution
Chennai, India, 600 006
Local Institution
New Dehli, India, 110025
Israel
Local Institution
Afula, Israel, 18101
Local Institution
Givataim, Israel, 53488
Local Institution
Hadera, Israel, 38101
Local Institution
Haifa, Israel, 31048
Local Institution
Haifa, Israel, 31096
Local Institution
Holon, Israel, 58100
Local Institution
Jerusalem, Israel, 91031
Local Institution
Kfar Saba, Israel, 44281
Local Institution
Kiryat Hadassah, Israel, 91120
Local Institution
Nahariya, Israel, 22100
Local Institution
Petach-Tikva, Israel, 49100
Local Institution
Safed, Israel, 13100
Local Institution
Tel Aviv, Israel, 64239
Local Institution
Tel Hashomer, Israel, 52621
Italy
Local Institution
Bollate, Italy, 20021
Local Institution
Bologna, Italy, 40138
Local Institution
Chieti Scalo, Italy, 66013
Local Institution
Cosenza, Italy, 87100
Local Institution
Ferrara, Italy, 44100
Local Institution
Firenze, Italy, 50134
Local Institution
Genova, Italy, 16128
Local Institution
Milano, Italy, 20132
Local Institution
Padova, Italy, 35128
Local Institution
Palermo, Italy, 90127
Local Institution
Pavia, Italy, 27100
Local Institution
Perugia, Italy, 06132
Local Institution
Piacenza, Italy, 29100
Local Institution
Pisa, Italy, 56124
Local Institution
Roma, Italy, 00168
Local Institution
Rozzano (Mi), Italy, 20089
Local Institution
San Daniele Del Friuli (Ud), Italy, 33038
Local Institution
Udine, Italy, 33100
Local Institution
Venezia, Italy, 30122
Local Institution
Vicenza, Italy, 36100
Local Institution
Vittorio Veneto (Tv), Italy, 31029
Korea, Republic of
Local Institution
Busan, Korea, Republic of, 602-702
Local Institution
Jongno-Gu, Korea, Republic of, 110-774
Local Institution
Seoul, Korea, Republic of, 135-710
Local Institution
Seoul, Korea, Republic of, 138736
Local Institution
Seoul, Korea, Republic of, 137-040
Local Institution
Seoul, Korea, Republic of, 120752
Mexico
Local Institution
Tijuana, Baja California, Mexico, 22500
Local Institution
Mexico, Distrito Federal, Mexico, 06726
Local Institution
Leon, Guanajuato, Mexico, 37320
Local Institution
Guadalajara, Jalisco, Mexico, 44130
Local Institution
Guadalajara, Jalisco, Mexico, 44280
Local Institution
Guadalajara, Jalisco, Mexico, 44200
Local Institution
Zapopan, Jalisco, Mexico, 45200
Local Institution
Monterrey, Nuevo Leon, Mexico, 64000
Local Institution
Monterrey, Nuevo Leon, Mexico, 64710
Local Institution
Culiacan, Sinaloa, Mexico, 80020
Local Institution
Culiacan, Sinaloa, Mexico, 80230
Local Institution
Xalapa, Veracruz, Mexico, 91020
Local Institution
Aguascalientes, Mexico, 20230
Local Institution
Chihuahua, Mexico, 31203
Local Institution
Durango, Mexico, 34080
Local Institution
Puebla, Mexico, 72000
Local Institution
Queretaro, Mexico, 76000
Local Institution
San Luis Potosi, Mexico, 78200
Local Institution
San Luis Potosi, Mexico, 78240
Norway
Local Institution
Alesund, Norway, 6026
Local Institution
Fredrikstad, Norway, 1606
Local Institution
Gjettum, Norway, 1346
Local Institution
Gjovik, Norway, 2819
Local Institution
Hamar, Norway, 2318
Local Institution
Oslo, Norway, 0407
Philippines
Local Institution
Cavite, Philippines, 4114
Local Institution
Davao City, Philippines, 8000
Local Institution
Pasig City, Philippines, 1600
Local Institution
Quezon City, Philippines, 1102
Poland
Local Institution
Arkonska 4, Poland, 71455
Local Institution
Bialystok, Poland, 15-276
Local Institution
Bydgoszcz, Poland, 85-681
Local Institution
Bydgoszcz, Poland, 85-650
Local Institution
Bydgoszcz, Poland, 85-168
Local Institution
Gdansk, Poland, 80-803
Local Institution
Gdynia, Poland, 81-423
Local Institution
Gdynia, Poland, 81-348
Local Institution
Lodz, Poland, 90-153
Local Institution
Lublin, Poland, 20-718
Local Institution
Lublin, Poland, 20-081
Local Institution
Poznan, Poland, 61-848
Local Institution
Przeworsk, Poland, 37-200
Local Institution
Szczecin, Poland, 70-111
Local Institution
Tarnobrzeg, Poland, 39-400
Local Institution
Warsaw, Poland, 01-809
Local Institution
Warsaw, Poland, 02-005
Local Institution
Warsawa, Poland, 02-776
Local Institution
Warszawa, Poland, 01-138
Local Institution
Warszawa, Poland, 02-018
Local Institution
Wroclaw, Poland, 53-114
Local Institution
Wroclaw, Poland, 51-124
Portugal
Local Institution
Guarda, Portugal, 6301-857
Local Institution
Lisboa, Portugal, 1769-001
Puerto Rico
Local Institution
San Juan, Puerto Rico, 00921
Local Institution
San Juan, Puerto Rico, 00909
Romania
Local Institution
Baia Mare, Romania, 430031
Local Institution
Bucharest, Romania, 050098
Local Institution
Bucharest, Romania, 022328
Local Institution
Bucharest, Romania, 030171
Local Institution
Targu Mures, Romania, 540136
Russian Federation
Local Institution
Arkhangelsk, Russian Federation, 163045
Local Institution
Kemerovo, Russian Federation, 650002
Local Institution
Moscow, Russian Federation, 111539
Local Institution
Moscow, Russian Federation, 105077
Local Institution
Moscow, Russian Federation, 119049
Local Institution
Moscow, Russian Federation, 127473
Local Institution
Novosibirsk, Russian Federation, 630055
Local Institution
Novosibirsk, Russian Federation, 630090
Local Institution
Rostov-On Don, Russian Federation, 344022
Local Institution
Ryazan, Russian Federation, 390026
Local Institution
Saint Petersburg, Russian Federation, 192242
Local Institution
Saint-Petersburg, Russian Federation, 196247
Local Institution
Saint-Petersburg, Russian Federation, 199106
Local Institution
Samara, Russian Federation, 443010
Local Institution
Saratov, Russian Federation, 410028
Local Institution
Saratov, Russian Federation, 410012
Local Institution
St Petersburg, Russian Federation, 194044
Local Institution
Tomsk, Russian Federation, 634012
Local Institution
Yaroslavl, Russian Federation, 150062
Singapore
Local Institution
Singapore, Singapore, 308433
Local Institution
Singapore, Singapore, 169608
South Africa
Local Institution
Bloemfontein, Free State, South Africa, 9301
Local Institution
Centurion, Gauteng, South Africa, 0157
Local Institution
Parktown, Gauteng, South Africa, 2193
Local Institution
Pretoria, Gauteng, South Africa, 0083
Local Institution
Pretoria, Gauteng, South Africa, 0084
Local Institution
Durban, Kwa Zulu Natal, South Africa, 4001
Local Institution
Pietermaritzburg, Kwa Zulu Natal, South Africa, 3201
Local Institution
Bellville, Western Cape, South Africa, 7530
Local Institution
George, Western Cape, South Africa, 6529
Local Institution
Somerset West, Western Cape, South Africa, 7130
Local Institution
Worcester, Western Cape, South Africa, 6850
Spain
Local Institution
Torrevieja, Alicante, Spain, 03186
Local Institution
Badalona, Barcelona, Spain, 08916
Local Institution
Majadahonda, Madrid, Spain, 28222
Local Institution
San Sebastian De Los Reyes, Madrid, Spain, 28702
Local Institution
Cadiz, Spain, 11009
Local Institution
Getafe, Spain, 28905
Local Institution
Girona, Spain, 17007
Local Institution
L'Hospitalet De Llobregat, Spain, 08907
Local Institution
Leon, Spain, 24008
Local Institution
Madrid, Spain, 28041
Local Institution
Madrid, Spain, 28029
Local Institution
Madrid, Spain, 28007
Local Institution
Madrid, Spain, 28040
Local Institution
Mourente, Spain, 36071
Local Institution
Pamplona, Spain, 31008
Local Institution
Salamanca, Spain, 37007
Local Institution
Sant Boi De Llobregat, Spain, 08830
Local Institution
Tarragona, Spain, 43007
Local Institution
Toledo, Spain, 45071
Local Institution
Valencia, Spain, 46026
Ukraine
Local Institution
Chernihiv, Ukraine, 14034
Local Institution
Dnipropetrovsk, Ukraine, 49000
Local Institution
Donetsk, Ukraine, 83045
Local Institution
Ivano-Frankivsk, Ukraine, 76018
Local Institution
Ivano-Frankivsk, Ukraine, 76008
Local Institution
Kharkiv, Ukraine, 61018
Local Institution
Kyiv, Ukraine, 03680
Local Institution
Lviv, Ukraine, 79010
Local Institution
Odesa, Ukraine, 65117
Local Institution
Ternopil, Ukraine, 46000
Local Institution
Vinnytsia, Ukraine, 21018
Local Institution
Zaporizhzhia, Ukraine, 69035
United Kingdom
Local Institution
Aberdeen, Aberdeenshire, United Kingdom, AB25 2ZN
Local Institution
Romford, Essex, United Kingdom, RM7 0AG
Local Institution
London, Greater London, United Kingdom, SW17 0QT
Local Institution
London, Greater London, United Kingdom, SE5 9RS
Local Institution
Manchester, Greater Manchester, United Kingdom, M23 9LT
Local Institution
Hull, Humberside, United Kingdom, HU3 2JZ
Local Institution
Nottingham, Nottinghamshire, United Kingdom, NG7 2UH
Local Institution
Bury St. Edmunds, Suffolk, United Kingdom, IP30 9QU
Local Institution
Coventry, West Midlands, United Kingdom, CV2 2DX
Local Institution
Dudley, West Midlands, United Kingdom, DY1 2HQ
Sponsors and Collaborators
Bristol-Myers Squibb
Pfizer
Investigators
Study Director: Bristol-Myers Squibb Bristol-Myers Squibb
  More Information

Additional Information:
No publications provided by Bristol-Myers Squibb

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Bristol-Myers Squibb
ClinicalTrials.gov Identifier: NCT00633893     History of Changes
Other Study ID Numbers: CV185-057, EUDRACT: 2007-004953-27
Study First Received: March 5, 2008
Results First Received: August 19, 2013
Last Updated: October 30, 2013
Health Authority: United States: Institutional Review Board
United States: Food and Drug Administration
Canada: Health Canada
Argentina: Administracion Nacional de Medicamentos, Alimentos y Tecnologia Medica
Brazil: National Health Surveillance Agency
Chile: Instituto de Salud Pública de Chile
Mexico: Federal Commission for Sanitary Risks Protection
Austria: Federal Office for Safety in Health Care
Denmark: Danish Medicines Agency
France: Ministry of Health
Germany: Ministry of Health
Israel: Ministry of Health
Italy: Ministry of Health
Norway: Directorate of Health
Spain: Spanish Agency of Medicines
South Africa: Department of Health
Turkey: Ministry of Health
United Kingdom: Medicines and Healthcare Products Regulatory Agency
Czech Republic: Ministry of Health
Hungary: Ministry of Health, Social and Family Affairs
Poland: Ministry of Health
Russia: Ministry of Health of the Russian Federation
Ukraine: Ministry of Health
Australia: Department of Health and Ageing Therapeutic Goods Administration
Hong Kong: Department of Health
India: Central Drugs Standard Control Organization
Korea: Food and Drug Administration
Malaysia: National Pharmaceutical Control Bureau
Taiwan: Department of Health
Romania: National Medicines Agency
Portugal: National Pharmacy and Medicines Institute

Additional relevant MeSH terms:
Embolism
Pulmonary Embolism
Thrombosis
Venous Thrombosis
Venous Thromboembolism
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases
Thromboembolism

ClinicalTrials.gov processed this record on July 29, 2014